Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study
Johnson & Johnson’s anti-tau monoclonal antibody failed to slow the progression of Alzheimer’s in patients with early-stage disease, marking the end of one of the compa...
Bayer’s experimental blood-thinner notches trial win in stroke prevention
Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.
Bayer’s asundexian hits phase III stroke goal in win for FXIa drugs
Detailed data will be forthcoming at a scientific congress, but Bayer AG’s positive top-line readout from its phase III study testing oral factor XIa (FXIa) inhibitor a...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial
Contineum Therapeutics reported a Phase 2 failure in multiple sclerosis on Thursday afternoon, but most analysts don’t seem to view the miss as catastrophic. Contineum...
Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena
Roche reports positive Phase III data of giredestrant for breast cancer Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory Clinical Trials Arena
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed - Fierce Biotech
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed Fierce Biotech
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint Clinical Trials Arena
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page Thermo Fisher Core Tools & Instruments
Track Danaher Core Tools & Instruments
Track Agilent Core Tools & Instruments
Track Merck KGaA Core Tools & Instruments
Track Illumina Core Tools & Instruments
Track Waters Core Tools & Instruments
Track Bruker Core Tools & Instruments
Track Sartorius Core Tools & Instruments
Track Mettler Toledo Core Tools & Instruments
Track PerkinElmer (Revvity) Core Tools & Instruments
Track Bio-Rad Core Tools & Instruments
Track Carl Zeiss Core Tools & Instruments
Track Leica Microsystems Core Tools & Instruments
Track Nikon Core Tools & Instruments